The media have reported news of a potential treatment for multiple sclerosis which uses technology similar to two of the Covid-19 vaccines. We’ve taken a closer look to find out more about the research behind the headlines.
The news story is based on a study published in the journal Science. German researchers injected messenger RNA (mRNA) into mice with an MS-like condition. The mRNA had been amended to instruct certain cells to produce substances similar to myelin, the fatty protein which acts as insulation for nerve cells. In MS, the immune system mistakenly attacks and destroys the myelin. The aim of this study was to induce the immune system to tolerate myelin, rather than attack it.
The researchers found that when the mRNA was injected into mice with MS-like disease, the mice developed less severe disease than would normally occur.
The research uses similar technology to two of the Covid-19 vaccines (Pfizer/BioNTech and Moderna) but used in a different way. Instead of using a vaccine to prime the immune system to recognise and fight off an infection, this approach uses the vaccine to teach the immune system to tolerate (or ignore) myelin.
So far, this approach has only been tested in mouse models of MS. The results are encouraging but translating a treatment from the MS-like condition in mice is not straightforward. Further research will need to study whether it is effective and safe in humans. However, the technology shows potential, and we will be keeping a close watch for any further developments.
A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis.
Krienke C, Kolb L, Diken E, et al.
Science 2021; 371(6525): 145-153.
Read the summary
Ponesimod (Ponvory) for relapsing remitting multiple sclerosis rejected by NICE
13 Oct 2021 - 00:00
The MS Trust is very disappointed that NICE does not recommend ponesimod (Ponvory) as an NHS treatment in England and Wales.
Multiple sclerosis and disease modifying drugs, what are my options?
28 Sep 2021 - 00:00
We interview Dr Sharmilee Gnanapavan, a Consultant Neurologist at Bart's Health to get some answers on what's new in the world of disease modifying drugs and multiple sclerosis.
New report highlights barriers to accessing Sativex across the UK
18 Aug 2021 - 00:00
Fewer than 13% of people in England eligible for Sativex can access it, according to a new report published today. People living in Wales, Scotland and Northern Ireland also face difficulties.
Move it for MS Nick's story
7 Oct 2021 - 00:00
Nick, was diagnosed with relapsing remitting Multiple Sclerosis at the start of the first lockdown. In this story we talk to him about how he coped with his diagnosis and how running helps him with his MS.
David's diary - Inclusion and diversity, where are we now?
6 Oct 2021 - 00:00
Just over a year ago we published a diary entry about Inclusivity and Diversity at the MS Trust. In this piece we take a look at what's changed since then and what we still need to do.
Flu season 2021
4 Oct 2021 - 00:00
This year is likely to involve a bigger flu vaccination programme in the UK, including for people with multiple sclerosis (MS), due to the circulation of Covid-19 at the same time. Here we discuss who's eligible for a flu jab on the NHS and how to get one.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.